Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.

Hassan B AwalSeshagiri Rao NandulaCleyton C DominguesFiona J DoreNabanita KunduBeda BrichacekMona FakhriAdrian ElzarkiNeeki AhmadiShauna SafaiMagan FossoRichard L AmdurSabyasachi Sen

Published in: Cardiovascular diabetology (2020)

In DKD subjects, Linagliptin promotes an increase in CXCR4 expression on CD34 + progenitor cells with a concomitant improvement in vascular and renal parameters at 12 weeks. Trial Registration Number NCT02467478 Date of Registration: 06/08/2015.

Keyphrases

type diabetes
chronic kidney disease
glycemic control
phase iii
poor prognosis
end stage renal disease
nk cells
study protocol
clinical trial
endothelial cells
randomized controlled trial
insulin resistance
metabolic syndrome
gestational age
skeletal muscle